Literature DB >> 3471620

Clinical evaluation of serum 3 beta-hydroxy-5-cholenoic acid in hepatobiliary diseases.

K Sugiyama, S Okuyama, M Imoto, K Okumura, K Takagi, T Satake.   

Abstract

Serum 3 beta-hydroxy-5-cholenoic acid (3 beta-OH-delta 5) was analyzed in 100 cases (90 patients with hepatobiliary diseases, 10 normal subjects) and its clinical significance investigated. The measurement of 3 beta-OH-delta 5 was performed by high performance liquid chromatography (HPLC) with immobilized 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) as the enzyme column. Esterified 3 beta-OH-delta 5 was measured after enzymatic hydrolysis with sulfatase and beta-glucuronidase. 3 beta-OH-delta 5 was hardly detected in normal cases. On the other hand, serum 3 beta-OH-delta 5 levels were remarkably high in cholestatic cases and also high in other cases with high bilirubin levels. The ratio of glycine- to taurine-conjugates (G/T ratio) was effective in discriminating cholestasis from hepatocellular damage such as in cases of acute hepatitis or fulminant hepatitis. More than 90% of the 3 beta-OH-delta 5, which is toxic, was sulfated or glucuronidated, suggesting detoxification by esterified bile acids. Significant increases of taurine-conjugated 3 beta-OH-delta 5 were observed in cases with pruritus, and a relationship between taurine-conjugated and pruritus was presumed. Therefore, analysis of 3 beta-OH-delta 5 is considered to be effective in clarifying the pathogenesis of hepatobiliary diseases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3471620     DOI: 10.1007/BF02774489

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  11 in total

1.  MEASUREMENT OF HUMAN SERUM BILE ACIDS BY GAS-LIQUID CHROMATOGRAPHY.

Authors:  D H SANDBERG; J SJOEVALL; K SJOEVALL; D A TURNER
Journal:  J Lipid Res       Date:  1965-04       Impact factor: 5.922

2.  Bile salt sulphates in cholestasis.

Authors:  A Stiehl
Journal:  Eur J Clin Invest       Date:  1974-02       Impact factor: 4.686

3.  Physiological basis of alterations in the relative conjugation of bile acids with glycine and taurine.

Authors:  J T Garbutt; L Lack; M P Tyor
Journal:  Am J Clin Nutr       Date:  1971-02       Impact factor: 7.045

4.  [Analysis of free, glycine-and taurine-conjugated individual bile acids using high performance liquid chromatography and immobilized 3 alpha-hydroxysteroid dehydrogenase in column form (author's transl)].

Authors:  S Okuyama
Journal:  Rinsho Byori       Date:  1981-05

5.  Bile acid glucuronides, II[1]. Isolation and identification of a chenodeoxycholic acid glucuronide from human plasma in intrahepatic cholestasis.

Authors:  P Back
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1976-02

6.  Excretion of 3beta-hydroxy-5-cholenoic and 3a-hydroxy-5a-cholanoic acids in urine of infants with biliary atresia.

Authors:  I Makino; J Sjövall; A Norman; B Strandvik
Journal:  FEBS Lett       Date:  1971-06-10       Impact factor: 4.124

7.  Phenobarbital effects in cholestatic liver diseases.

Authors:  J R Bloomer; J L Boyer
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

8.  Determination of 3 beta-hydroxy-5-cholenoic acid in serum of hepatobiliary diseases--its glucuronidated and sulfated conjugates.

Authors:  H Takikawa; H Otsuka; T Beppu; Y Seyama
Journal:  Biochem Med       Date:  1985-06

9.  The formation of lithocholic acid, chenodeoxycholic acid and alpha- and beta-muricholic acids from cholesterol incubated with rat-liver mitochondria.

Authors:  K A Mitropoulos; N B Myant
Journal:  Biochem J       Date:  1967-05       Impact factor: 3.857

10.  Identification of mono- and dihydroxy bile acids in human feces by gas-liquid chromatography and mass spectrometry.

Authors:  P Eneroth; B Gordon; R Ryhage; J Sjövall
Journal:  J Lipid Res       Date:  1966-07       Impact factor: 5.922

View more
  1 in total

1.  Cholesterol and bile acid synthesis in Hep G2 cells. Metabolic effects of 26- and 7 alpha-hydroxycholesterol.

Authors:  N B Javitt; K Budai
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.